The cost-effectiveness issue of adjuvant trastuzumab in early breast cancer

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.7, Iss.12, 2006-08, pp. : 1617-1625

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost Effectiveness of Trastuzumab in the Adjuvant Treatment of Early Breast Cancer: A Lifetime Model

By Millar J. Alasdair Millward Michael J.

PharmacoEconomics, Vol. 25, Iss. 5, 2007-01 ,pp. : 429-442

Adis International

Access to resources Recommend Favorite

Updated Cost-Effectiveness Analysis of Trastuzumab for Early Breast Cancer: A UK Perspective Considering Duration of Benefit, Long-Term Toxicity and Pattern of Recurrence

By Hall Peter S. Hulme Claire McCabe Christopher Oluboyede Yemi Round Jeff Cameron David A.

PharmacoEconomics, Vol. 29, Iss. 5, 2011-05 ,pp. : 415-432

Adis International

Access to resources Recommend Favorite

Adjuvant trastuzumab promising but costly for breast cancer

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 500, 2006-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Methodological Issues in Evaluating Cost Effectiveness of Adjuvant Aromatase Inhibitors in Early Breast Cancer: A Need for Improved Modelling to Aid Decision Making

By Annemans Lieven

PharmacoEconomics, Vol. 26, Iss. 5, 2008-01 ,pp. : 409-423

Adis International

Access to resources Recommend Favorite

In defence of trastuzumab for early breast cancer

Inpharma, Vol. 1, Iss. 1521, 2006-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite